Skip to main content
. 2021 Jul 20;46(3):197. doi: 10.3892/or.2021.8148

Figure 6.

Figure 6.

TβRI-TβRII-Fc chimeric receptor inhibits B16 melanoma tumor growth in vivo. B16 cells expressing Control-Fc, TβRII-Fc, and TβRI-TβRII-Fc chimeric receptors were subcutaneously inoculated into left flank region of C57/BL6 mice. The experiment was repeated twice. (A) Representative primary tumors formed by B16 melanoma cells expressing Control-Fc, TβRII-Fc and TβRI-TβRII-Fc chimeric receptors on day 26 (marked by red dashed circles). Scale bar, 10 mm. (B) Tumor growth was monitored for 26 days. Control-Fc (n=11), TβRII-Fc (n=9), and TβRI-TβRII-Fc (n=11). Error bars, SE. (C) The changes in body weight of the mice inoculated with B16 cells expressing Control-Fc, TβRII-Fc, and TβRI-TβRII-Fc chimeric receptors. Error bars, SE. **P<0.01. TβRI, TGF-β type I receptor; TβRII, TGF-β type II receptor; NS, not significant.